Coagulation and the fibrin network in rheumatic disease: A role beyond haemostasis

Nature Reviews Rheumatology

Volumn 8, Issue 12, 2012, Pages 738-746

  Hoppe, Berthold ^a   Dörner, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; D DIMER; ETANERCEPT; FC RECEPTOR; FIBRIN; FIBRINOGEN; HLA DRB1 ANTIGEN; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE ACTIVATED RECEPTOR; PROTHROMBIN; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; ALLELE; ANCA ASSOCIATED VASCULITIS; BLOOD CLOTTING; BLOOD FLOW; BLOOD VISCOSITY; CELL ACTIVATION; CONNECTIVE TISSUE DISEASE; DEEP VEIN THROMBOSIS; ENDOTHELIUM CELL; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HUMAN; IMMUNOSTIMULATION; LUNG EMBOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; VASCULITIS; WEGENER GRANULOMATOSIS;

BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; FEMALE; FIBRIN; HEMOSTASIS; HUMANS; IMMUNITY, INNATE; MALE; PLATELET ACTIVATION; RHEUMATIC DISEASES; VENOUS THROMBOEMBOLISM;

EID: 84870721810     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.184     Document Type: Review

References (83)

1. Naranjo, A. et al. Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study. Arthritis Res. Ther. 10, R30 (2008).
2. Symmons, D. P. & Gabriel, S. E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol. 7, 399-408 (2011).
3. Sawamura, A. et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb. Res. 124, 608-613 (2009).
4. Smeeth, L. et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 367, 1075-1079 (2006).
5. Hoppe, B., Burmester, G. R. & Dörner, T. Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). Curr. Opin. Rheumatol. 23, 299-304 (2011).
6. Tripodi, A. de Groot, P. G. & Pengo, V. Antiphospholipid syndrome: Laboratory detection, mechanisms of action and treatment. J. Intern. Med. 270, 110-122 (2011).
7. Lim, W. Crowther, M. A. & Eikelboom, J. W. Management of antiphospholipid antibody syndrome: A systematic review. JAMA 295, 1050-1057 (2006).
8. Cervera, R. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82, 299-308 (2003).
9. Cervera, R. Morbidity and mortality in the antiphospholipid syndrome during a 5 year period: A multicentre prospective study of 1,000 patients. Ann. Rheum. Dis. 68, 1428-1432 (2009).
10. Cohen, D., Berger, S. P., Steup-Beekman, G. M., Bloemenkamp, K. W. & Bajema, I. M. Diagnosis and management of the antiphospholipid syndrome. BMJ 340, c2541 (2010).
11. Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303-1307 (2003).
12. Zöller, B., Li, X., Sundquist, J. & Sundquist, K. Risk of pulmonary embolism in patients with autoimmune disorders: A nationwide follow-up study from Sweden. Lancet 379, 244-249 (2012).
13. Busso, N. & Hamilton, J. A. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum. 46, 2268-2279 (2002).
14. Sanchez-Pernaute, O. et al. A fibrin based model for rheumatoid synovitis. Ann. Rheum. Dis. 62, 1135-1138 (2003).
15. So, A. K. et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J. Thromb. Haemost. 1, 2510-2515 (2003).
16. Matta, F., Singala, R., Yaekoub, A. Y., Najjar, R. & Stein, P. D. Risk of venous thromboembolism with rheumatoid arthritis. Thromb. Haemost. 101, 134-138 (2009).
17. Bacani, A K., Gabriel, S. E., Crowson, C. S., Heit, J. A. & Matteson, E. L. Noncardiac vascular disease in rheumatoid arthritis: Increase in venous thromboembolic events? Arthritis Rheum. 64, 53-61 (2012).
18. Choi, H. K., Hernan, M. A., Seeger, J. D., Robins, J. M. & Wolfe, F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359, 1173-1177 (2002).
19. Micha, R. et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol. 108, 1362-1370 (2011).
20. Askling, J. & Dixon, W. Influence of biological agents on cardiovascular disease in rheumatoid arthritis. Ann. Rheum. Dis. 70, 561-562 (2011).
21. Greenberg, J. D. et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 576-582 (2011).
22. Ingegnoli, F. et al. Activation of inflammation, coagulation and fibrinolysis in patients with rheumatoid arthritis: Inhibition by tumour necrosis factor alpha blockade [abstract]. Ann. Rheum. Dis. 67 (Suppl. 1), A30 (2008).
23. Ingegnoli, F. et al. Anti-tumor necrosis factor alpha therapy normalises fibrinolysis impairment in patients with active rheumatoid arthritis. Clin. Exp. Rheumatol. 28, 254-257 (2010).
24. Ingegnoli, F. et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-alpha blockade. J. Autoimmun. 31, 175-179 (2008).
25. Ingegnoli, F. et al. Reduction of haemostatic and inflammatory biomarkers by tumor necrosis factor-alpha blockade in patients with rheumatoid arthritis [abstract]. Ann. Rheum. Dis. 66 (Suppl. 1), A56 (2007).
26. Agirbasli, M., Inanc, N., Baykan, O.A. & Direskeneli, H. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin. Exp. Rheumatol. 24, 580-583 (2006).
27. Sarabi, Z. S. et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum. 53, 609-612 (2005).
28. Haga, H. J., Jacobsen, E. M. & Peen, E. Incidence of thromboembolic events in patients with primary Sjogren's syndrome. Scand. J. Rheumatol. 37, 127-129 (2008).
29. Schramm, G. A. & Schrah, G. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: Results of a pooled analysis of noninterventional trials in adult and adolescent women. Contraception 84, 390-401 (2011).
30. Cushman, M. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology. Am. J. Med. 117, 19-25 (2004).
31. Hansson, P. O., Welin, L., Tibblin, G. & Eriksson, H. Deep vein thrombosis and pulmonary embolism in the general population - 'The study of men born in 1913'. Arch. Intern. Med. 157, 1665-1670 (1997).
32. Merkel, P. A. et al. Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis: The Wegener's clinical occurrence of thrombosis (WeCLOT) study. Ann. Intern. Med. 142, 620-626 (2005).
33. Stassen, P. M., Derks, R. P., Kallenberg, C. G. & Stegeman, C. A. Venous thromboembolism in ANCA-associated vasculitis - incidence and risk factors. Rheumatology (Oxford) 47, 530-534 (2008).
34. Smith, B. D. & La Celle, P. L. Blood-viscosity and thrombosis: Clinical considerations. Prog. Hemost. Thromb. 6, 179-201 (1982).
35. Murdaca, G. et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224, 309-317 (2012).
36. Dippold, W., Wittig, B., Schwaeble, W., Mayet, W. & Meyer zum Büschenfelde, K. H. Expression of intercellular-adhesion molecule 1 (ICAM 1, CD54) in colonic epithelial cells. Gut 34, 1593-1597 (1993).
37. Guillevin, L. & Dörner, T. Vasculitis: Mechanisms involved and clinical manifestations. Arthritis. Res. Ther. 9 (Suppl. 2), S9 (2007).
38. Delvaeye, M. & Conway, E. M. Coagulation and innate immune responses: Can we view them separately? Blood 114, 2367-2374 (2009).
39. van Hinsbergh, V. W. Endothelium - role in regulation of coagulation and inflammation. Semin. Immunopathol. 34, 93-106 (2012).
40. Foster, W., Carruthers, D., Lip, G. Y. & Blann, A. D. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: Effect of treatment. J. Rheumatol. 37, 711-716 (2010).
41. Egerer, K. et al. sE-selectin for stratifying outcome in rheumatoid arthritis. Arthritis Rheum. 49, 546-548 (2003).
42. Schouten, M., Wiersinga, W. J., Levi, M. & van der Poll, T. Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 83, 536-545 (2008).
43. Peters, M. J., Nurmohamed, M. T., van Eijk, I. C., Verkleij, C. J. & Marx, P. F. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1232-1233 (2009).
44. Carmeliet, P. et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424 (1994).
45. Nurden, A. T. Platelets, inflammation and tissue regeneration. Thromb. Haemost. 105 (Suppl. 1), S13-S33 (2011).
46. Boilard, E. et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327, 580-583 (2010).
47. Esmon, C. T. Coagulation and inflammation. J. Endotoxin Res. 9, 192-198 (2003).
48. Undas, A. et al. Thrombin generation in rheumatoid arthritis: Dependence on plasma factor composition. Thromb. Heamost. 104, 224-230 (2010).
49. Monroe, D. M., Hoffman, M. & Roberts, H. R. Platelets and thrombin generation. Atherioscler. Thromb. Vasc. Biol. 22, 1381-1389 (2002).
50. Morris, R., Winyard, P. G., Blake, D. R. & Morris, C. J. Thrombin in inflammation and healing: Relevance to rheumatoid arthritis. Ann. Rheum. Dis. 53, 72-79 (1994).
51. Petaja, J. Inflammation and coagulation. An overview. Thromb. Res. 127 (Suppl. 2), S34-S37 (2011).
52. Marty, I. et al. Amelioration of collagen-induced arthritis by thrombin inhibition. J. Clin. Invest. 107, 631-640 (2001).
53. Varisco, P. A. et al. Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann. Rheum. Dis. 59, 781-787 (2000).
54. Flick, M. J. et al. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood 117, 6326-6337 (2011).
55. Danckwardt, S. et al. The prothrombin 3' end formation signal reveals a unique architecture that is sensitive to thrombophilic gain of function mutations. Blood 104, 428-435 (2004).
56. Hoppe, B., Burmester, G. R. & Häupl, T. Prothrombin 20210G>A genotype and C reactive protein level. Blood 118, 4495-4496 (2011).
57. Mosesson, M. W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost. 3, 1894-1904 (2005).
58. Lanir, N. et al. Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration. J. Immunol. 140, 2340-2349 (1988).
59. Loof, T. G. et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 118, 2589-2598 (2011).
60. Hoppe, B. et al. Fibrinogen and factor XIII A subunit genotypes interactively influence C reactive protein levels during inflammation. Ann. Rheum. Dis. 71, 1163-1169 (2012).
61. Lim, B. C., Ariëns, R. A., Carter, A. M., Weisel, J. W. & Grant, P. J. Genetic regulation of fibrin structure and function: Complex gene-environment interactions may modulate vascular risk. Lancet 361, 1424-1431 (2003).
62. Reiner, A. P. et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: The Coronary Artery Risk Development in Young Adults (CARDIA) study. J. Thromb. Haemost. 4, 1279-1287 (2006).
63. Siegerink, B., Rosendaal, F. R. & Algra, A. Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J. Thromb. Haemost. 7, 385-390 (2009).
64. Ariens, R. A., Lai, T. S., Weisel, J. W., Greenberg, C. S. & Grant, P. J. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100, 743-754 (2002).
65. Van Meegeren, M. E., Roosendaal, G., Barten-van Rijbroek, A.D., Mastbergen, S.C. & Lafeber, F. P. Intra-articular blood coagulation aggravates joint damage after a bleed in a canine in vivo model [abstract]. Osteoarthritis Cartilage 20, S49 (2012).
66. Senior, R. M., Skogen, W. F., Griffin, G. L. & Wilner, G. D. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J. Clin. Invest. 77, 1014-1019 (1986).
67. Persson, K., Russell, W., Mörgelin, M. & Herwald, H. The conversion of fibrinogen to fibrin at the surface of curliated Escherichia coli bacteria leads to the generation of proinflammatory fibrinopeptides. J. Biol. Chem. 278, 31884-31890 (2003).
68. Sokolove, J., Zhao, X. & Robinson, W. Citrullinated fibrinogen stimulates TNF release via TLR-4 and citrullinated fibrinogen immune complexes co-stimulate through TLR-4 and the Fc gamma receptor [abstract]. Clin. Immunol. 135 (Suppl.), S38 (2010).
69. Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fc gamma receptor. Arthritis Rheum. 63, 53-62 (2011).
70. Flick, M. J. et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac 1 is critical for host inflammatory response in vivo. J. Clin. Invest. 113, 1596-1606 (2004).
71. Flick, M. J. et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J. Clin. Invest. 117, 3224-3235 (2007).
72. Klareskog, L., Rönnelid, J., Lundberg, K., Padyukov, L. & Alfredsson, L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26, 651-675 (2008).
73. Kuhn, K. A. et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116, 961-973 (2006).
74. Hill, J. A., Al-Bishri, J. Gladman, D. D., Cairns, E. & Bell, D. A. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J. Rheumatol. 33, 2115-2119 (2006).
75. Sokolove, J. et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 7, e35296 (2012).
76. Hill, J. A. et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4 I E transgenic mice. J. Exp. Med. 205, 967-979 (2008).
77. Belkin, A. M. et al. Transglutaminase-mediated oligomerization of the fibrin(ogen) alphaC domains promotes integrin-dependent cell adhesion and signaling. Blood 105, 3561-3568 (2005).
78. Liu, X. F. & Piela-Smith, T. H. Fibrin(ogen)-induced expression of ICAM 1 and chemokines in human synovial fibroblasts. J. Immunol. 165, 5255-5261 (2000).
79. Skogen, W. F., Senior, R. M., Griffin, G. L. & Wilner, G. D. Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 71, 1475-1479 (1988).
80. Gaitonde, S. D. & Ballou, S. P. Deep venous thrombosis in dermatomyositis. J. Rheumatol. 35, 2288 (2008).
81. Selva O'Callaghan, A., Fernandez-Lugue, A., Martinez-Gomez, X., Labirua-Ituburu, A. & Vilardell-Tarres, M. Venous thromboembolism in patients with dermatomyositis and polymyositis. Clin. Exp. Rheumatol. 29, 846-849 (2011).
82. Weidner, S. Hafezi-Rachti, S. & Rupprecht, H. D. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 55, 146-149 (2006).
83. Allenbach, Y. et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: A systematic retrospective study on 1,130 patients. Ann. Rheum. Dis. 68, 564-567 (2009).